PURPOSE: (18)F-FDG PET is increasingly used for imaging of vessel wall inflammation. However, limited data are available on the impact of methodological variables, i.e. prescan fasting glucose, FDG circulation time and injected FDG dose, and of different FDG uptake parameters, in vascular FDG PET imaging. METHODS: Included in the study were 195 patients who underwent vascular FDG PET/CT of the aorta and the carotids. Arterial standardized uptake values (meanSUVmax), target-to-background ratios (meanTBRmax) and FDG blood-pool activity in the superior vena cava (SVC) and the jugular veins (JV) were quantified. Vascular FDG uptake values classified according to the tertiles of prescan fasting glucose levels, the FDG circulation time, and the injected FDG dose were compared using ANOVA. Multivariate regression analyses were performed to identify the potential impact of all variables described on the arterial and blood-pool FDG uptake. RESULTS: Tertile analyses revealed FDG circulation times of about 2.5 h and prescan glucose levels of less than 7.0 mmol/l, showing a favorable relationship between arterial and blood-pool FDG uptake. FDG circulation times showed negative associations with aortic meanSUVmax values as well as SVC and JV FDG blood-pool activity, but positive correlations with aortic and carotid meanTBRmax values. Prescan glucose levels were negatively associated with aortic and carotid meanTBRmax and carotid meanSUVmax values, but were positively correlated with SVC blood-pool uptake. The injected FDG dose failed to show any significant association with vascular FDG uptake. CONCLUSION: FDG circulation times and prescan blood glucose levels significantly affect FDG uptake in the aortic and carotid walls and may bias the results of image interpretation in patients undergoing vascular FDG PET/CT. The injected FDG dose was less critical. Therefore, circulation times of about 2.5 h and prescan glucose levels less than 7.0 mmol/l should be preferred in this setting.
PURPOSE: (18)F-FDG PET is increasingly used for imaging of vessel wall inflammation. However, limited data are available on the impact of methodological variables, i.e. prescan fasting glucose, FDG circulation time and injected FDG dose, and of different FDG uptake parameters, in vascular FDG PET imaging. METHODS: Included in the study were 195 patients who underwent vascular FDG PET/CT of the aorta and the carotids. Arterial standardized uptake values (meanSUVmax), target-to-background ratios (meanTBRmax) and FDG blood-pool activity in the superior vena cava (SVC) and the jugular veins (JV) were quantified. Vascular FDG uptake values classified according to the tertiles of prescan fasting glucose levels, the FDG circulation time, and the injected FDG dose were compared using ANOVA. Multivariate regression analyses were performed to identify the potential impact of all variables described on the arterial and blood-pool FDG uptake. RESULTS: Tertile analyses revealed FDG circulation times of about 2.5 h and prescan glucose levels of less than 7.0 mmol/l, showing a favorable relationship between arterial and blood-pool FDG uptake. FDG circulation times showed negative associations with aortic meanSUVmax values as well as SVC and JV FDG blood-pool activity, but positive correlations with aortic and carotid meanTBRmax values. Prescan glucose levels were negatively associated with aortic and carotid meanTBRmax and carotid meanSUVmax values, but were positively correlated with SVC blood-pool uptake. The injected FDG dose failed to show any significant association with vascular FDG uptake. CONCLUSION: FDG circulation times and prescan blood glucose levels significantly affect FDG uptake in the aortic and carotid walls and may bias the results of image interpretation in patients undergoing vascular FDG PET/CT. The injected FDG dose was less critical. Therefore, circulation times of about 2.5 h and prescan glucose levels less than 7.0 mmol/l should be preferred in this setting.
Authors: Ahmed Tawakol; Raymond Q Migrino; Udo Hoffmann; Suhny Abbara; Stuart Houser; Henry Gewirtz; James E Muller; Thomas J Brady; Alan J Fischman Journal: J Nucl Cardiol Date: 2005 May-Jun Impact factor: 5.952
Authors: J H F Rudd; Z A Fayad; J Machac; P L Weissberg; J R Davies; E A Warburton; A A Tawakol; H W Strauss; V Fuster Journal: Atherosclerosis Date: 2006-11-27 Impact factor: 5.162
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Cathy Anne Pinto; Christopher Tong; Ash Rafique; Richard Hargeaves; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Mootaz Eldib; Jason Bini; Olivier Lairez; David D Faul; Niels Oesingmann; Zahi A Fayad; Venkatesh Mani Journal: Am J Nucl Med Mol Imaging Date: 2015-06-15
Authors: Jacek Kwiecinski; Daniel S Berman; Sang-Eun Lee; Damini Dey; Sebastien Cadet; Martin L Lassen; Guido Germano; Maurits A Jansen; Marc R Dweck; David E Newby; Hyuk-Jae Chang; Mijin Yun; Piotr J Slomka Journal: J Nucl Med Date: 2018-09-13 Impact factor: 10.057
Authors: Pavlos P Kafouris; Iosif P Koutagiar; Alexandros T Georgakopoulos; Nikoletta K Pianou; Marinos G Metaxas; George M Spyrou; Constantinos D Anagnostopoulos Journal: Int J Cardiovasc Imaging Date: 2019-01-31 Impact factor: 2.357
Authors: Sune F Pedersen; Trine P Ludvigsen; Helle H Johannesen; Johan Löfgren; Rasmus S Ripa; Adam E Hansen; Anders J Ettrup; Berit Ø Christoffersen; Henrik D Pedersen; Lisbeth H Olsen; Liselotte Højgaard; Andreas Kjær Journal: Am J Nucl Med Mol Imaging Date: 2014-08-15
Authors: Jose J Rico-Jimenez; Michael J Serafino; Sebina Shrestha; Xi Chen; Wihan Kim; Jessie Adame; L Maximillan Buja; Deborah Vela; Brian E Applegate; Javier A Jo Journal: Atherosclerosis Date: 2019-04-19 Impact factor: 5.162
Authors: Kaitlin A Quinn; Joel S Rosenblum; Casey A Rimland; K Bates Gribbons; Mark A Ahlman; Peter C Grayson Journal: Semin Arthritis Rheum Date: 2019-07-24 Impact factor: 5.532